Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03206177 · OUTCOME

Median Progression Free Survival (Months)

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary · Source last updated 2024-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
through study completion, an average of 3 years

What was measured

Progression free survival is defined as time from when the patient is registered on the study until RECIST v1.1 documented disease progression as per the protocol or death.

Analysis population: Patients who received at least four cycles of study drug.

Groups in this outcome

Paclitaxel/Carboplatin + Galunisertib

Galunisertib: Galunisertib 150mg po BID day 4-17 Paclitaxel: Paclitaxel 175 mg/m2 over 3 hours Carboplatin: IV day 1 Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Paclitaxel/Carboplatin + Galunisertib23

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Paclitaxel/Carboplatin + Galunisertib6.55Not reported5.4210.81Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.42
        upper Limit
        10.81
        value
        6.55
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
Progression free survival is defined as time from when the patient is registered on the study until RECIST v1.1 documented disease progression as per the protocol or death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Galunisertib: Galunisertib 150mg po BID day 4-17 Paclitaxel: Paclitaxel 175 mg/m2 over 3 hours Carboplatin: IV day 1 Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
    id
    OG000
    title
    Paclitaxel/Carboplatin + Galunisertib
param Type
MEDIAN
population Description
Patients who received at least four cycles of study drug.
reporting Status
POSTED
time Frame
through study completion, an average of 3 years
title
Median Progression Free Survival (Months)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice